Premium
Novel adsorptive type apheresis device Immunopure for ulcerative colitis from clinical perspectives based on clinical trials: Japan and Europe
Author(s) -
Endo Yoshihiro,
Yonekawa Motoki,
Kukita Kazutaka,
Katagiri Masaki,
Matsumoto Takayuki,
Kawasaki Keisuke,
Yanai Shunichi,
Kato Shingo,
Kani Kazuhito,
Ogawa Tomonari,
Kitamura Kazuya,
Hasegawa Izumi,
Inoue Yusuke,
Doi Takuya,
Higuchi Kazuhide,
Kawakami Ken,
Kakimoto Kazuki,
Nakamura Hiroki
Publication year - 2021
Publication title -
therapeutic apheresis and dialysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.415
H-Index - 53
eISSN - 1744-9987
pISSN - 1744-9979
DOI - 10.1111/1744-9987.13661
Subject(s) - medicine , ulcerative colitis , apheresis , refractory (planetary science) , platelet , adsorption , clinical trial , colitis , clinical practice , gastroenterology , chromatography , disease , composite material , materials science , chemistry , family medicine , organic chemistry
Several adsorptive type devices for ulcerative colitis are used for the induction of remission in patients with active severe disease worldwide. In 2020, the novel apheresis device Immunopure for ulcerative colitis was launched in Japan. Immunopure, like the polyethylene terephthalate column, uses polyarylate, a type of polyester resin, as the adsorbent. Similar to the cellulose acetate column, Immunopure is filled with adsorbent beads and expected to provide ease of use, with minimal risk of column clogging. Immunopure adsorbs leukocytes and platelets, especially activated platelets and platelet‐leukocyte aggregates. In this article, the capability of Immunopure is evaluated from clinical perspective based on a clinical trial in Japan/Europe. As a result, Immunopure is comparable to other products in clinical effectiveness and indicated for the treatment of patients with refractory moderate ulcerative colitis, making it highly useful in clinical practice.